Glaxo Wellcome PLC continued its cautious march back into the vaccine business by unveiling a DNA vaccine collaboration with Powderject Pharmaceuticals PLC, a fledgling Oxford, England land based company. The agreement is a bold bet that delivering synthetic chunks of DNA directly into infected cells will prove an effective therapy in disorders ranging from HIV to hepatitis B and cancer.